Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels

Apellis Pharmaceuticals Inc said on Tuesday its experimental drug for a blood disorder showed greater improvement in patients’ hemoglobin levels than Alexion Pharmaceuticals Inc’s Soliris, in a late-stage study.